Literature DB >> 18685493

E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer.

Jose Pontes1, Miguel Srougi, Priscila M A Borra, Marcos F Dall' Oglio, Leopoldo A Ribeiro-Filho, Katia R M Leite.   

Abstract

OBJECTIVES: E-cadherin and beta-catenin are adhesion molecules responsible for the maintenance of normal epithelial cell phenotype. A disturbance in epithelial cell adhesion, which leads to a more invasive and metastatic phenotype, is a hallmark of tumor progression. Several immunohistochemical studies have reported a strong correlation between loss of their expression to higher stage and grade in prostate carcinoma, but their influence in metastatic process is not yet known. The aim of this study is to verify the role of adhesion molecules in the progression of prostate cancer (PC), assessing the expression of E-cadherin and beta-catenin in bone metastasis.
MATERIALS AND METHODS: Twenty-eight bone metastases of prostate carcinoma were submitted to immunohistochemistry analysis for E-cadherin and beta-catenin expression. In 6 patients, we were able to assess the expression of the adhesion molecules in the primary tumors and their respective metastases. The definition of normal expression for both antibodies was strong and diffuse expression in more than 70% of tumor cells.
RESULTS: In bone metastases, there was loss of expression of E-cadherin and beta-catenin in 86% and 82%, respectively. Among the primary tumors, E-cadherin and beta-catenin expression was normal in 83% and 50% cases, respectively. Considering the 6 patients with paired primary and bone metastasis, we found loss of expression for both E-cadherin and beta-catenin in most of the cases.
CONCLUSIONS: Comparing primary PC and its metastasis, we showed persistent loss of E-cadherin and beta-catenin expression. This phenomenon may be related to metastatic potential in PC, because we have shown underexpression for E-cadherin and beta-catenin in 86% and 82% of bone metastases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 18685493     DOI: 10.1097/PAI.0b013e3181640bca

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  22 in total

1.  Low magnitude mechanical signals mitigate osteopenia without compromising longevity in an aged murine model of spontaneous granulosa cell ovarian cancer.

Authors:  Gabriel M Pagnotti; Benjamin J Adler; Danielle E Green; M Ete Chan; Danielle M Frechette; Kenneth R Shroyer; Wesley G Beamer; Janet Rubin; Clinton T Rubin
Journal:  Bone       Date:  2012-05-11       Impact factor: 4.398

2.  Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.

Authors:  Catarina Ferreira; João Lobo; Luís Antunes; Paula Lopes; Carmen Jerónimo; Rui Henrique
Journal:  Virchows Arch       Date:  2018-07-13       Impact factor: 4.064

3.  Epithelial-Mesenchymal Transition Markers β-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study.

Authors:  Tumay Ipekci; Ferhat Ozden; Betul Unal; Caner Saygin; Didem Uzunaslan; Erhan Ates
Journal:  Pathol Oncol Res       Date:  2015-06-04       Impact factor: 3.201

4.  Immunohistochemical investigation of F344/N rat islet cell tumors from national toxicology program studies.

Authors:  Christopher Koivisto; Gordon P Flake; Holly Kolenda-Roberts; Tiwanda Masinde; Grace E Kissling; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2012-04-03       Impact factor: 1.902

5.  Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.

Authors:  Aaron P Putzke; Aviva P Ventura; Alexander M Bailey; Canan Akture; John Opoku-Ansah; Müge Celiktaş; Michael S Hwang; Douglas S Darling; Ilsa M Coleman; Peter S Nelson; Holly M Nguyen; Eva Corey; Muneesh Tewari; Colm Morrissey; Robert L Vessella; Beatrice S Knudsen
Journal:  Am J Pathol       Date:  2011-05-04       Impact factor: 4.307

6.  Suppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis.

Authors:  Fei Gao; Abdulrahman Alwhaibi; Harika Sabbineni; Arti Verma; Wael Eldahshan; Payaningal R Somanath
Journal:  Cancer Lett       Date:  2017-06-07       Impact factor: 8.679

7.  Loss of E-cadherin promotes prostate cancer metastasis via upregulation of metastasis-associated gene 1 expression.

Authors:  Liangsheng Fan; Hongyan Wang; Xi Xia; Yumei Rao; Xiangyi Ma; Ding Ma; Peng Wu; Gang Chen
Journal:  Oncol Lett       Date:  2012-09-21       Impact factor: 2.967

8.  Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.

Authors:  Maahum Haider; Xiaotun Zhang; Ilsa Coleman; Nolan Ericson; Lawrence D True; Hung-Ming Lam; Lisha G Brown; Melanie Ketchanji; Belinda Nghiem; Bryce Lakely; Roger Coleman; Bruce Montgomery; Paul H Lange; Martine Roudier; Celestia S Higano; Jason H Bielas; Peter S Nelson; Robert L Vessella; Colm Morrissey
Journal:  Clin Exp Metastasis       Date:  2015-12-14       Impact factor: 5.150

9.  Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation.

Authors:  Wenyan Lu; Heather N Tinsley; Adam Keeton; Zhican Qu; Gary A Piazza; Yonghe Li
Journal:  Eur J Pharmacol       Date:  2008-11-09       Impact factor: 4.432

10.  Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells.

Authors:  R Mitchell Baldwin; Alan Morettin; Genevieve Paris; Isabelle Goulet; Jocelyn Côté
Journal:  Cell Cycle       Date:  2012-11-27       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.